- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Healthy potentially undervalued
Hong Kong Pharmaceuticals & Biotech Healthy potentially undervalued
Results
12
Companies which are potentially undervalued and in an acceptable financial position.
12 companies
Innovent Biologics
Market Cap: HK$163.3b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally.
1801
HK$93.80
7D
-1.1%
1Y
-3.8%
United Laboratories International Holdings
Market Cap: HK$17.2b
An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.
3933
HK$8.72
7D
-5.5%
1Y
-45.4%
China Resources Pharmaceutical Group
Market Cap: HK$30.4b
An investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally.
3320
HK$4.85
7D
0.1%
1Y
-8.4%
3SBio
Market Cap: HK$43.7b
An investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of China, the United States, and internationally.
1530
HK$17.53
7D
-2.4%
1Y
-47.7%
Shanghai Junshi Biosciences
Market Cap: HK$40.6b
A biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China.
1877
HK$19.54
7D
0.3%
1Y
-38.9%
Duality Biotherapeutics
Market Cap: HK$17.4b
A clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally.
9606
HK$192.60
7D
-0.5%
1Y
-46.2%
Everest Medicines
Market Cap: HK$10.6b
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
1952
HK$30.20
7D
11.4%
1Y
-57.2%
InnoCare Pharma
Market Cap: HK$31.3b
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.
9969
HK$14.94
7D
4.5%
1Y
-23.8%
Grand Pharmaceutical Group
Market Cap: HK$18.3b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials.
512
HK$5.24
7D
0.1%
1Y
-37.5%
China Medical System Holdings
Market Cap: HK$28.5b
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.
867
HK$11.82
7D
-4.9%
1Y
-12.4%
RemeGen
Market Cap: HK$70.7b
A biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.
9995
HK$80.70
7D
-6.4%
1Y
4.7%
Shanghai Henlius Biotech
Market Cap: HK$36.6b
Engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases.
2696
HK$67.30
7D
0.5%
1Y
-19.5%